

Pneumococcal conjugate vaccine trial: PNEUVAC TRIAL

Submission date 22/07/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 22/07/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 01/12/2016	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

The pneumococcus bacterium is a leading problem in HIV-infected adults. It is the leading cause of bacterial meningitis and a principal cause of bloodstream infection/blood poisoning (pneumococcal disease). HIV-infected individuals who have had one attack of serious pneumococcal infection have a 1 in 4 chance of a further attack in the next 12 months. Disease is often severe and death occurs in 20% of cases. Vaccines for preventing pneumococcal disease have been available for over 90 years, based on vaccinating with the outer lining of the bacterium, the capsule. The vaccine recommended for adults contains capsule for 23 types of pneumococci (23-valent). There are over 90 types but most disease is caused by these 23 types. Immunisation with the 23-valent vaccine was tested in HIV-infected adults in Uganda, but the vaccine failed to provide protection. A second generation of pneumococcal vaccines has been licensed for use in children. As the vaccine was developed primarily for use in children, information on the role of the vaccine in adults and particularly HIV-infected adults is lacking. The aim of this study is to test the effectiveness of the new vaccine to prevent pneumococcal disease in HIV-infected adults.

Who can participate?

Patients aged over 15 who have recovered from a serious pneumococcal infection and are willing to have an HIV test.

What does the study involve?

Participants are randomly allocated to receive either the active vaccine or a placebo (dummy) injection. The vaccination consists of two injections given into the upper arm, 4-6 weeks apart. Participants are followed-up every three months. If a participant becomes unwell they are requested to attend the Queen Elizabeth Central Hospital to be investigated for pneumococcal infection. Transport costs are provided for routine visits and those requested by the Doctor. Blood tests are carried out at routine visits and when participants are unwell – this will be 10-25 ml of blood. An HIV test is performed on the first blood sample. The results of the HIV test are available to the participants. In addition to blood tests a samples from the nose is taken at each visit to investigate for the presence of the pneumococcus in the nose.

What are the possible benefits and risks of participating?

Benefits include increased access to clinical services both for routine follow up of HIV and more rapid assessment of acute illness episodes, with greater access to diagnostic services than available routinely within the hospital. The study will encourage uptake of HIV test results with appropriate support and thereby increase access to HIV services and beneficial treatments. Risks include possible side effects from vaccination, although work to date suggests this is a very safe vaccine with low rates of reaction. There will be discomfort associated with the blood sampling and nasal swabbing, although these will be transitory. Because a great deal of research going on is HIV associated, there is the potential for individuals to be identified as HIV-infected by association with the study. Confidentiality and integration of services into routine care will minimize this risk.

Where is the study run from?

Queen Elizabeth Central Hospital, Blantyre, Malawi

When is the study starting and how long is it expected to run for?

February 2003 to October 2007

Who is funding the study?

The Wellcome Trust (UK)

Who is the main contact?

Prof. Neil French

neil.french@lshtm.ac.uk

Contact information

Type(s)

Scientific

Contact name

Mr Neil French

Contact details

Malawi-Liverpool-Wellcome Trust Labs

Blantyre

Malawi

Box 3009

+265 (0)9 207898

neil.french@lshtm.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00371878

Protocol serial number

061230

Study information

Scientific Title

Investigation of the humoral immune response to pneumococcal polysaccharides and the role of a conjugate pneumococcal vaccine in secondary prevention of invasive pneumococcal disease in human immunodeficiency virus (HIV)-infected Africans

Acronym

PNEUVAC

Study objectives

Efficacy of a seven-valent pneumococcal conjugate vaccine to prevent recurrent episodes of vaccine serotype invasive pneumococcal disease (IPD) in a primarily human immunodeficiency virus (HIV)-infected adult population.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. University of Malawi, College of Medicine Research and Ethics Committee, 12/01/2001, ref: P. 99/00/101
2. Liverpool School of Tropical Medicine Research and Ethics Committee, 20/12/2000, ref: 00.60

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Invasive pneumococcal disease in HIV-infected Africans

Interventions

Participants are recruited from individuals who are convalescing from a known invasive pneumococcal disease event. They are randomised into two arms in a 1:1 ratio to receive two doses of vaccine one month apart. In the active arm the vaccine is Prevenar® (Wyeth pharmaceuticals seven-valent pneumococcal conjugate vaccine with a CRM carrier protein). In the control arm participants receive a matching saline placebo.

Vaccine is given as a 0.5 ml injection into the non-dominant deltoid muscle. Participants are followed up at three-monthly intervals and encouraged to attend the hospital when sick for evaluation of their illness. Individuals will be followed as long as they remain alive and within the study area until the follow-up censure date which was set at 31st October 2007. Total follow up is 798 person years with a median follow up time of 1.24 years [Range 2 days to 4.66 years].

Intervention Type

Biological/Vaccine

Primary outcome(s)

Vaccine serotype invasive pneumococcal disease

Key secondary outcome(s)

1. All invasive pneumococcal disease death
2. All cause pneumonia

Completion date

31/10/2007

Eligibility

Key inclusion criteria

1. Confirmed case of IPD discharged from hospital
2. Resident of Blantyre and its immediately neighbouring districts
3. Willing to attend Queen Elizabeth Central Hospital (QECH) when sick
4. Aged over 15 years, either sex
5. Willing to have HIV testing performed on stored serum

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Pregnancy
2. Previous pneumococcal vaccine
3. Active acute systemic illness - following recovery participant may be recruited
4. Past hypersensitivity reaction to vaccination
5. Bed-ridden or life expectancy judged to be less than three months

Date of first enrolment

28/02/2003

Date of final enrolment

31/05/2007

Locations

Countries of recruitment

Malawi

Study participating centre
Malawi-Liverpool-Wellcome Trust Labs
Blantyre
Malawi
Box 3009

Sponsor information

Organisation
University of Liverpool (UK)

ROR
<https://ror.org/04xs57h96>

Funder(s)

Funder type
Charity

Funder Name
Wellcome Trust (UK) (grant ref: 061230)

Alternative Name(s)

Funding Body Type
Private sector organisation

Funding Body Subtype
International organizations

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	04/03/2010		Yes	No
Results article	results	01/09/2016		Yes	No